Literature DB >> 25608146

Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT.

William Makis1, Karey McCann, Alexander J B McEwan.   

Abstract

An 18-year-old girl presented with a 3-year history of a recurrent skull base mass confirmed to be a rhabdoid papillary meningioma. The tumor was octreotide avid and metastatic to the lungs, thoracic lymph nodes, and bones, and she was referred for PRRT (peptide receptor radionuclide therapy) with 177Lu DOTATATE. After 3 induction treatment cycles of 177Lu DOTATATE, she experienced significant improvements in her symptoms; however, just before the fourth treatment, she developed cervical spinal cord compression and passed away shortly thereafter. The use of 177Lu DOTATATE therapy in the management of rhabdoid papillary meningioma warrants further research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25608146     DOI: 10.1097/RLU.0000000000000669

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

Authors:  Majid Assadi; Seyed Javad Rekabpour; Abdullatif Amini; Habibollah Dadgar; Reza Nemati; Ali Gholamrezanezhad; Iraj Nabipour; Esmail Jafari; Hojjat Ahmadzadehfar
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

2.  Dynamic 68Ga-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas.

Authors:  Jana Ivanidze; Michelle Roytman; Myrto Skafida; Sean Kim; Shannon Glynn; Joseph R Osborne; Susan C Pannullo; Sadek Nehmeh; Rohan Ramakrishna; Theodore H Schwartz; Jonathan P S Knisely; Eaton Lin; Nicolas A Karakatsanis
Journal:  Radiol Imaging Cancer       Date:  2022-03

3.  PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes.

Authors:  Michelle Roytman; Sean Kim; Shannon Glynn; Charlene Thomas; Eaton Lin; Whitney Feltus; Rajiv S Magge; Benjamin Liechty; Theodore H Schwartz; Rohan Ramakrishna; Nicolas A Karakatsanis; Susan C Pannullo; Joseph R Osborne; Jonathan P S Knisely; Jana Ivanidze
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

4.  Antibody-Drug Conjugate to Treat Meningiomas.

Authors:  Kai Chen; Yingnan Si; Jianfa Ou; Jia-Shiung Guan; Seulhee Kim; Patrick Ernst; Ya Zhang; Lufang Zhou; Xiaosi Han; Xiaoguang Margaret Liu
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.